×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KALV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
06:30 am
kalv
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Medium
Report
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
11/5
06:30 am
kalv
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/4
07:20 am
kalv
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals [Yahoo! Finance]
Medium
Report
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals [Yahoo! Finance]
11/4
07:05 am
kalv
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
Medium
Report
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
11/4
07:00 am
kalv
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
Medium
Report
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
10/28
06:30 am
kalv
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
Medium
Report
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
10/18
06:30 am
kalv
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
Medium
Report
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
10/18
06:22 am
kalv
Togo suspends Russia's ride-hailing app Yango [Yahoo! Finance Canada]
Medium
Report
Togo suspends Russia's ride-hailing app Yango [Yahoo! Finance Canada]
Date
Time
Symbol
Company Name
Action
%Chg
9/5/2024
06:30 am
KALV
kalvista pharmaceuticals, inc.
BEAT
Report
-0.9%
kalvista pharmaceuticals, inc.
7/11/2024
06:30 am
KALV
kalvista pharmaceuticals, inc.
MISS
Report
-0.8%
kalvista pharmaceuticals, inc.
3/11/2024
06:30 am
KALV
kalvista pharmaceuticals, inc.
MISS
Report
-10.4%
kalvista pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
07:20 pm
kalv
Form 4 KalVista Pharmaceuticals For: Nov 17 Filed by: Palleiko Benjamin L
Medium
Report
Form 4 KalVista Pharmaceuticals For: Nov 17 Filed by: Palleiko Benjamin L
11/19
07:19 pm
kalv
Form 4 KalVista Pharmaceuticals For: Nov 17 Filed by: Yea Christopher
Medium
Report
Form 4 KalVista Pharmaceuticals For: Nov 17 Filed by: Yea Christopher
11/19
07:18 pm
kalv
Form 4 KalVista Pharmaceuticals For: Nov 17 Filed by: Audhya Paul K.
Medium
Report
Form 4 KalVista Pharmaceuticals For: Nov 17 Filed by: Audhya Paul K.
11/14
04:01 pm
kalv
Form SC 13G/A KalVista Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
Low
Report
Form SC 13G/A KalVista Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
11/14
03:58 pm
kalv
Form SC 13G/A KalVista Pharmaceuticals Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
Low
Report
Form SC 13G/A KalVista Pharmaceuticals Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
11/14
12:02 pm
kalv
Form SC 13G KalVista Pharmaceuticals Filed by: Vestal Point Capital, LP
Medium
Report
Form SC 13G KalVista Pharmaceuticals Filed by: Vestal Point Capital, LP
11/13
12:55 pm
kalv
Form SC 13G KalVista Pharmaceuticals Filed by: Capital World Investors
Low
Report
Form SC 13G KalVista Pharmaceuticals Filed by: Capital World Investors
11/12
04:06 pm
kalv
Form SC 13G/A KalVista Pharmaceuticals Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A KalVista Pharmaceuticals Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/9
Q1/2019 7/31/2019 EPS -0.420 ZacksConsensus -0.610 ActVsEst 0.190 - Beat
9.9%
3/23 Form SC 13G KalVista Pharmaceuticals Filed by: Ikarian Capital, LLC 8.8%
4/9 KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference 8.4%
12/7 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%
11/29 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.0%
7/19 Form 4 KalVista Pharmaceuticals For: Jul 17 Filed by: Cha Albert 4.4%
9/30 Form 4 KalVista Pharmaceuticals For: Sep 26 Filed by: SOLAND DANIEL B 4.3%
6/16 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
5/14 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
10/25 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. 3.2%
3/23 Form SC 13G KalVista Pharmaceuticals Filed by: Ikarian Capital, LLC 8.8%
4/9 KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference 8.4%
12/7 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%
11/29 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.0%
7/19 Form 4 KalVista Pharmaceuticals For: Jul 17 Filed by: Cha Albert 4.4%
9/30 Form 4 KalVista Pharmaceuticals For: Sep 26 Filed by: SOLAND DANIEL B 4.3%
6/16 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
5/14 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
10/25 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. 3.2%
TOP News Decliners
3/10
Form 10-Q KalVista Pharmaceuticals For: Jan 31
-14.8%
3/10 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results -13.7%
4/30 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.7%
5/31 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.7%
12/26 Form 4 KalVista Pharmaceuticals For: Dec 20 Filed by: Crockett Thomas Andrew -6.8%
12/3 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. -6.8%
2/22 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.8%
7/1 Form 8-K KalVista Pharmaceuticals For: Jun 26 -4.5%
9/4 KalVista Pharmaceuticals: Our Verdict [Seeking Alpha] -4.3%
5/15 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its price target raised by analysts at Roth Capital from $25.00 to $30.00. They now have a "buy" rating on the stock. -4.2%
3/10 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results -13.7%
4/30 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.7%
5/31 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.7%
12/26 Form 4 KalVista Pharmaceuticals For: Dec 20 Filed by: Crockett Thomas Andrew -6.8%
12/3 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. -6.8%
2/22 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.8%
7/1 Form 8-K KalVista Pharmaceuticals For: Jun 26 -4.5%
9/4 KalVista Pharmaceuticals: Our Verdict [Seeking Alpha] -4.3%
5/15 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its price target raised by analysts at Roth Capital from $25.00 to $30.00. They now have a "buy" rating on the stock. -4.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: